Geron Corp (NASDAQ:GERN)

CAPS Rating: 2 out of 5

A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.


Player Avatar TMFBlacknGold (98.64) Submitted: 4/25/2011 2:23:57 PM : Outperform Start Price: $4.97 GERN Score: -71.05

Cancer vaccines based on telomerase reverse transcriptase (TERT), which repairs damaged telomeres. Telomeres are the caps at the end of chromosomes. These shorten every time a cell divides as a natural check and balance to cell division. Some cancer cells - the ones that become tumors - have the TERT enzyme and can repair these shortened telomeres. So, the proposed vaccine will include make TERT a target of the body's immune system, thus targeting runaway cancer cells. The science behind these drugs is worth the risk.

Report this Post 2 Replies
Member Avatar whomonkyoulus (28.41) Submitted: 5/27/2011 6:00:11 AM
Recs: 0

But won't that cause auto-immune disease and reduced longevity? Sounds like a bad plan to me.

Member Avatar TMFBlacknGold (98.64) Submitted: 5/30/2011 10:50:40 PM
Recs: 0

TERT isn't produced by normal body cells, so cells that divide uncontrollably or produce too many errors during replication are themselves targeted by the immune system. Also, there are many ways to deliver APIs to an affected area. Think about IMGN or SGEN. They have Ph.Ds up the wazoo for a reason!

Featured Broker Partners